JP2018500337A5 - - Google Patents

Download PDF

Info

Publication number
JP2018500337A5
JP2018500337A5 JP2017532675A JP2017532675A JP2018500337A5 JP 2018500337 A5 JP2018500337 A5 JP 2018500337A5 JP 2017532675 A JP2017532675 A JP 2017532675A JP 2017532675 A JP2017532675 A JP 2017532675A JP 2018500337 A5 JP2018500337 A5 JP 2018500337A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequences
acid sequence
cell
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500337A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/067178 external-priority patent/WO2016100980A1/en
Publication of JP2018500337A publication Critical patent/JP2018500337A/ja
Publication of JP2018500337A5 publication Critical patent/JP2018500337A5/ja
Pending legal-status Critical Current

Links

JP2017532675A 2014-12-19 2015-12-21 炭酸脱水酵素ｉｘ特異的キメラ抗原受容体およびその使用方法 Pending JP2018500337A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094596P 2014-12-19 2014-12-19
US62/094,596 2014-12-19
PCT/US2015/067178 WO2016100980A1 (en) 2014-12-19 2015-12-21 Carbonic anhydrase ix specific chimeric antigen receptors and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2018500337A JP2018500337A (ja) 2018-01-11
JP2018500337A5 true JP2018500337A5 (enExample) 2019-02-07

Family

ID=55273519

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017532675A Pending JP2018500337A (ja) 2014-12-19 2015-12-21 炭酸脱水酵素ｉｘ特異的キメラ抗原受容体およびその使用方法

Country Status (11)

Country Link
US (3) US10870705B2 (enExample)
EP (1) EP3233901A1 (enExample)
JP (1) JP2018500337A (enExample)
KR (1) KR20170093248A (enExample)
CN (1) CN108064251A (enExample)
AU (1) AU2015364240A1 (enExample)
BR (1) BR112017013177A2 (enExample)
CA (1) CA2968555A1 (enExample)
IL (1) IL252366A0 (enExample)
RU (1) RU2017125735A (enExample)
WO (1) WO2016100980A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017125531A (ru) * 2014-12-19 2019-01-21 Дана-Фарбер Кэнсер Инститьют, Инк. Химерные антигенные рецепторы и способы их применения
WO2018119198A1 (en) * 2016-12-22 2018-06-28 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
JP2021512875A (ja) * 2018-02-02 2021-05-20 カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． 細胞免疫療法の組み合わせ
JP7649239B2 (ja) * 2018-11-30 2025-03-19 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド キメラ抗原受容体ファクトリおよびその使用方法
CN109705225B (zh) * 2019-01-21 2022-02-22 徐州医科大学 一种抗人caix抗原的嵌合抗原受体及其应用
WO2020226612A1 (en) * 2019-05-06 2020-11-12 Navi Bio-Therapeutics, Llc Anti-carbonic anhydrase ix antibody
TWI869344B (zh) * 2019-05-06 2025-01-11 納維再生科技股份有限公司 抗-碳酸酐酶ix抗體
CN112552408B (zh) * 2019-09-10 2022-09-20 普米斯生物技术(珠海)有限公司 靶向caix抗原的纳米抗体及其应用
WO2021055973A2 (en) * 2019-09-20 2021-03-25 Navi Bio-Therapeutics, Inc. Personalized cancer immunotherapy
CN113045665B (zh) * 2021-03-22 2022-05-13 徐州医科大学 一种hvem共刺激信号驱动的caix-car-t细胞及其制备方法和应用
CA3217029A1 (en) 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
EP4321526A4 (en) 2022-02-11 2026-04-15 C Biomex Co Ltd Peptide ligand targeting carbonic anhydrase IX, peptide construction comprising it, and associated uses
CN116102662A (zh) * 2022-10-10 2023-05-12 武汉波睿达生物科技有限公司 一种靶向ca9的融合嵌合抗原受体、重组表达载体及其应用
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統
WO2025064539A1 (en) 2023-09-19 2025-03-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Herv-e antibodies and methods of their use
WO2026096443A1 (en) * 2024-10-30 2026-05-07 Link Cell Therapies Inc. Synthetic receptors for control and specific treatment of renal cell carcinoma with car t cells
WO2026117666A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Bispecific antibodies for treating cancer
WO2026117664A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Engineered cells and uses thereof for treating cancer
WO2026148120A2 (en) 2024-12-31 2026-07-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Car with dual-variable domain and enhanced tcr-signaling targeting ct-rcc-1 peptide and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2572277A1 (en) 2004-06-30 2006-01-12 Cordis Corporation Intraluminal medical device having asymetrical members and method for optimization
EP1979379B1 (en) * 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
FR2933058B1 (fr) 2008-06-30 2010-08-27 Zf Systemes De Direction Nacam Sas Dispositif d'assistance au verrouillage d'une colonne de direction
DE102008030837A1 (de) 2008-06-30 2010-01-14 Siemens Aktiengesellschaft Elektrochrome Formulierung, Herstellungsverfahren dazu und elektrochromes organisches Bauelement
EP2934532B1 (en) * 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3789487A1 (en) 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
FR3023477B1 (fr) 2014-07-10 2017-11-24 Oreal Utilisation cosmetique de l'acide spiculisporique comme actif deodorant

Similar Documents

Publication Publication Date Title
RU2017125735A (ru) Химерные антигенные рецепторы против карбоангидразы ix и способы их применения
JP2019510733A5 (enExample)
AU2017302668B9 (en) Combination therapies of chimeric antigen receptors and PD-1 inhibitors
JP2018504094A5 (enExample)
FI3703750T3 (fi) B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja
JP2016508725A5 (enExample)
RU2018111462A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
JP2018506981A5 (enExample)
JP2020530989A5 (enExample)
FI4063397T3 (fi) Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
IL268620B2 (en) Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment
JP2017513478A5 (enExample)
JP2018508215A5 (enExample)
JP2017500869A5 (enExample)
JP2017508466A5 (enExample)
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
IL275311B1 (en) Vcar preparations and methods of use
RU2018135247A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК
JP2015527070A5 (enExample)
RU2017137251A (ru) Комбинация антител cd30xcd16 для терапии с антагонистом pd-1
JP2018532407A5 (enExample)
JP2020512973A5 (enExample)
JP2018518939A5 (enExample)
JP2015509717A5 (enExample)
RU2022102250A (ru) Клетка